Critical Path Institute

32 articles about Critical Path Institute

• Multistakeholder Collaborations are Vital to Advancing Technologies in Parkinson's

  7/6/2023

  Critical Path Institute and the Center for Health + Technology at University of Rochester announced the release of two seminal publications about digital health technologies for Parkinson's.

• Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation

  9/27/2022

  Critical Path Institute named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer.

• 

  Research Ramps Up in Alzheimer's, Parkinson's, MS and ALS

  9/19/2022

  Research on Alzheimer's, specifically in neuroscience, continues with the Alzheimer's Drug Discovery Foundation, Critical Path Institute, Abbvie, AlzeCure Pharma and more. 

• C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases

  9/14/2022

  Critical Path Institute (C-Path) has announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).

• C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation

  6/9/2022

  Critical Path Institute announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator.

• C-Path Welcomes Alphabet Clinical Policy and Strategy Head, Former FDA Commissioner to Board

  5/19/2021

  Critical Path Institute announced the appointment of Robert M. Califf, MD, MACC, head of Clinical Policy and Strategy for Google parent company Alphabet's Verily Life Sciences and Google Health divisions, to C-Path's Board of Directors.

• Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

  12/16/2020

  Diamyd Medical and the Critical Path Institute are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative T1D integrated database.

• Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program

  6/22/2020

  Collaboration between the transplant community, industry, and regulatory agencies develops biomarker aimed to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients.

• C-Path's Transplant Therapeutics Consortium Receives Acceptance of Letter of Intent for iBox Scoring System (Composite Biomarker Panel) as a Reasonably Likely Surrogate Endpoint

  6/17/2020

  Biomarker aims to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients.

• C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies

  10/15/2019

  The Critical Path Institute and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration regulations commonly known as the Animal Rule.

• Parkinson’s UK AndCritical Path Institute Launch The Critical Path For Parkinson’s (CPP) Consortium

  10/15/2015

• Critical Path Institute’s Polycystic Kidney Disease Outcomes Consortium Secures FDA Qualification For Enrichment Biomarker In Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  8/31/2015

• Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy

  8/3/2015

• Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium

  7/22/2015

• Critical Path Institute Announces Appointments Of Peter Hutt, Alan Levin, And Paula Olsiewski To Its Board Of Directors

  6/25/2015

• Critical Path Institute Secures Regulatory Support for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker

  6/1/2015

• Critical Path Institute Launches New Neonatal Consortium

  5/19/2015

• Critical Path Institute Launches New Neonatal Consortium

  5/19/2015

• Critical Path Institute Release: Host For New TB Clinical Trial Data-Sharing Platform Selected

  5/5/2015

• Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers

  4/28/2015